2019-nCoV S-RBD Dhexdhexaadinta Qalabka Tijaabada Kahortagga Jirka (qaabka dahabka kolloyalka)
Hordhac
Waqtigan xaadirka ah, dhammaan tallaallada musharraxiinta ee 2019-nCoV ee horumarinta kiliinikada waxaa lagu maamulaa duritaanka muruqa.Talaalka muruqa ama maqaarka hoose wuxuu u horseedi karaa kicin xoog leh oo ah serum IgG
In ka badan 180 musharax oo tallaal, oo ku saleysan dhowr goobood oo kala duwan ayaa hadda ku jira horumar ka dhan ah 2019-nCoV.
borotiinka S waa bartilmaameedka ugu weyn ee ka hortagga unugyada difaaca;
Qaar badan oo ka mid ah unugyada difaaca jirka waxay beegsadaan RBD ee borotiinka S.
Sida loo qiimeeyo waxtarka tallaalka 2019-nCoV? --- Dhexdhexaadinta Qalabka Tijaabada Kahortagga Jirka
Faa'iidada
Baaritaanka tallaalka ka hor
Kahor tallaalka, musharrixiinta waxay ogaan karaan antibody-ka-hortagga RBD si loo go'aamiyo haddii tallaalku lagama maarmaan yahay;
Inta badan tallaalada waa la daboolay
Waxay ogaan kartaa ka-hortagga difaaca jirka ee ay soo saaraan inta badan tallaalada suuqa;
Degdeg ah oo ku habboon
Qalliinku waa sahlan yahay, qalab lagu ogaanayo looma baahna, natiijooyinka waxaa lagu heli karaa 15 daqiiqo gudahood.
Shaqada aqoonsiga
Waxay kala saari kartaa kahortaga difaaca jirka ee 2019-nCoV ee uu soo saaray tallaalka 2019-nCoV ama ka-hortagga uu soo saaray caabuqa 2019-nCoV ee nooc ka mid ah tallaallada, sida tallaalka Viral vector (aan-ku-dabayn), tallaalka saldhigga RNA iyo tallaalka borotiinka hoosaadka. ;
Baaritaanka dhiigga oo dhan
Tijaabada dhiigga oo dhan ayaa ka dhigaysa qalliinka mid ku habboon;
Baaxadda codsiga
Tallaalka ka hor
Go'aanso haddii ay qaadeen cudurka 'coronavirus' cusub iyo inay weli u baahan yihiin in la tallaalo;
Muddada tallaalka
Go'aanso in antibody-ka-hortagga cusub la soo saaray iyo in kale;
Marxaladda dambe ee tallaalka
Marka loo eego aagga cudurka faafa ee 2019-nCoV, waxaa la soo jeediyay in la ogaado jiritaanka 2019-nCoV ka-hortagga kahortagga si joogto ah saddexdii biloodba mar.
Qaybaha
Qaybaha | Waxyaabaha ugu muhiimsan | Tirada soo darida (Tirada) | ||
1 T/Kit | 20 T/Kit | 50 T/Qalabka | ||
Kaarka tijaabada | Xariijimo tijaabo ah oo ka kooban dahab kolloidal ah oo lagu sumadeeyay kahortaga-bini'aadamka IgG antibody, dahab kolloidle ah oo ku suntan anti-digaag IgY antibody, 2019-nCoV S-RBD borotiinka dib u habeynta, Digaag IgY antibody | 1 pc | 20 pcs | 50 pcs |
Tusaalaha lagu qasi karo | 0.01M Fosfate xalinta, 0.5% Tween-20 | 0.5ml | 5ml | 10ml |
Waxqabadka
Hecin reagent | Baaritaanka dhexdhexaadinta fayraska serum ee bukaan-socodka | Wadarta | |
Wanagsan | xun | ||
Wanagsan | Wanagsan | 84 | 9 |
xun | xun | 8 | 198 |
Wadarta | Wadarta | 92 | 207 |
Dareenka bukaan socodka | Dareenka bukaan socodka | 84/92 91.30% (95% CI: 83.58%~96.17%) | |
Gaar ahaan bukaan-socodka | Gaar ahaan bukaan-socodka | 198/207 95.65% (95%CI: 91.91%~97.99%) | |
Saxnaanta | Saxnaanta | 282/299 94.31% (95% CI: 91.05%~96.65%) |
Waxqabadka Hecin reagent ee lidka ku ah Habka Isbarbardhigga ee shaybaarrada serum/plasma.
Hecin reagent | Baaritaanka dhexdhexaadinta fayraska serum ee bukaan-socodka | Wadarta | |
Wanagsan | xun | ||
Wanagsan | 84 | 8 | 92 |
xun | 8 | 199 | 207 |
Wadarta | 92 | 207 | 299 |
Dareenka bukaan socodka | 84/92 91.30% (95% CI: 83.58%~96.17%) | ||
Gaar ahaan bukaan-socodka | 199/207 96.14% (95% CI: 92.53%~98.32%) | ||
Saxnaanta | 283/299 94.65% (95% CI: 91.46%~96.91%) |
Waxqabadka Hecin reagent ka dhanka ah Habka Isbarbardhigga ee shaybaarada dhiigga oo dhan.
Habka Imtixaanka
Shahaadada Diiwaangelinta
JT08-1T
JT08-5T
JT08-50T